Table 1.
Baseline characteristics of COVID-19 positive patients, by race/ethnicity and severity status.
| Severe | Non-severe | |||||||
|---|---|---|---|---|---|---|---|---|
| NHW (N = 9,140) | AAPI (N = 590) | Hispanic (N = 3,786) | NHB (N = 3,346) | NHW (N = 99,882) | AAPI (N = 10,276) | Hispanic (N = 56,226) | NHB (N = 42,477) | |
| Age categories (%) | ||||||||
| < 1 years | 1601 (17.5%) | 122 (20.7%) | 767 (20.3%) | 733 (21.9%) | 9655 (9.7%) | 965 (9.4%) | 6154 (10.9%) | 4686 (11.0%) |
| 1 to < 5 years | 2811 (30.8%) | 197 (33.4%) | 1174 (31.0%) | 910 (27.2%) | 22018 (22.0%) | 2802 (27.3%) | 11892 (21.2%) | 9147 (21.5%) |
| 5 to < 12 years | 1893 (20.7%) | 133 (22.5%) | 773 (20.4%) | 568 (17.0%) | 27547 (27.6%) | 3191 (31.1%) | 17205 (30.6%) | 12991 (30.6%) |
| 12 to < 16 years | 1243 (13.6%) | 60 (10.2%) | 489 (12.9%) | 482 (14.4%) | 18276 (18.3%) | 1433 (13.9%) | 10430 (18.6%) | 7721 (18.2%) |
| 16 to < 21 years | 1592 (17.4%) | 78 (13.2%) | 583 (15.4%) | 653 (19.5%) | 22386 (22.4%) | 1885 (18.3%) | 10545 (18.8%) | 7932 (18.7%) |
| Gender | ||||||||
| Female | 4208 (46.0%) | 255 (43.2%) | 1728 (45.6%) | 1580 (47.2%) | 50682 (50.7%) | 4968 (48.3%) | 28412 (50.5%) | 21408 (50.4%) |
| Male | 4932 (54.0%) | 335 (56.8%) | 2058 (54.4%) | 1766 (52.8%) | 49200 (49.3%) | 5308 (51.7%) | 27814 (49.5%) | 21069 (49.6%) |
| Hospital | ||||||||
| A | 1459 (16.0%) | 37 (6.3%) | 154 (4.1%) | 389 (11.6%) | 14323 (14.3%) | 530 (5.2%) | 1226 (2.2%) | 6069 (14.3%) |
| B | 1113 (12.2%) | 95 (16.1%) | 317 (8.4%) | 646 (19.3%) | 24713 (24.7%) | 1960 (19.1%) | 4289 (7.6%) | 9949 (23.4%) |
| C | 1031 (11.3%) | 57 (9.7%) | 801 (21.2%) | 163 (4.9%) | 4415 (4.4%) | 242 (2.4%) | 3880 (6.9%) | 848 (2.0%) |
| D | 390 (4.3%) | 29 (4.9%) | 159 (4.2%) | 257 (7.7%) | 4647 (4.7%) | 471 (4.6%) | 2245 (4.0%) | 4443 (10.5%) |
| E | 420 (4.6%) | 13 (2.2%) | 60 (1.6%) | 48 (1.4%) | 7581 (7.6%) | 322 (3.1%) | 1094 (1.9%) | 1047 (2.5%) |
| F | 712 (7.8%) | 71 (12.0%) | 595 (15.7%) | 250 (7.5%) | 1907 (1.9%) | 239 (2.3%) | 1833 (3.3%) | 661 (1.6%) |
| G | 754 (8.2%) | 28 (4.7%) | 92 (2.4%) | 153 (4.6%) | 7547 (7.6%) | 742 (7.2%) | 768 (1.4%) | 1314 (3.1%) |
| H | 232 (2.5%) | 1 (0.2%) | 16 (0.4%) | 35 (1.0%) | 4529 (4.5%) | 109 (1.1%) | 283 (0.5%) | 710 (1.7%) |
| I | 1156 (12.6%) | 85 (14.4%) | 183 (4.8%) | 517 (15.5%) | 8530 (8.5%) | 1098 (10.7%) | 1801 (3.2%) | 5844 (13.8%) |
| J | 882 (9.6%) | 33 (5.6%) | 643 (17.0%) | 501 (15.0%) | 8173 (8.2%) | 526 (5.1%) | 5824 (10.4%) | 3404 (8.0%) |
| K | 105 (1.1%) | 25 (4.2%) | 273 (7.2%) | 64 (1.9%) | 6783 (6.8%) | 2568 (25.0%) | 28574 (50.8%) | 5440 (12.8%) |
| L | 182 (2.0%) | 88 (14.9%) | 320 (8.5%) | 100 (3.0%) | 1942 (1.9%) | 1151 (11.2%) | 3170 (5.6%) | 1057 (2.5%) |
| M | 704 (7.7%) | 28 (4.7%) | 173 (4.6%) | 223 (6.7%) | 4792 (4.8%) | 318 (3.1%) | 1239 (2.2%) | 1691 (4.0%) |
| Entry time | ||||||||
| 03/2020–06/2020 | 136 (1.5%) | 17 (2.9%) | 163 (4.3%) | 122 (3.6%) | 907 (0.9%) | 190 (1.8%) | 1935 (3.4%) | 891 (2.1%) |
| 07/2020–10/2020 | 241 (2.6%) | 19 (3.2%) | 166 (4.4%) | 108 (3.2%) | 5454 (5.5%) | 433 (4.2%) | 4967 (8.8%) | 1760 (4.1%) |
| 11/2020–02/2021 | 753 (8.2%) | 47 (8.0%) | 346 (9.1%) | 291 (8.7%) | 16011 (16.0%) | 1240 (12.1%) | 10089 (17.9%) | 5262 (12.4%) |
| 03/2021–06/2021 | 720 (7.9%) | 32 (5.4%) | 277 (7.3%) | 309 (9.2%) | 7916 (7.9%) | 445 (4.3%) | 3007 (5.3%) | 4056 (9.5%) |
| 07/2021–10/2021 | 1063 (11.6%) | 37 (6.3%) | 394 (10.4%) | 485 (14.5%) | 13868 (13.9%) | 818 (8.0%) | 6095 (10.8%) | 6477 (15.2%) |
| 11/2021–02/2022 | 3050 (33.4%) | 193 (32.7%) | 1320 (34.9%) | 1136 (34.0%) | 33830 (33.9%) | 3746 (36.5%) | 19028 (33.8%) | 16290 (38.4%) |
| 03/2022–06/2022 | 1662 (18.2%) | 120 (20.3%) | 577 (15.2%) | 447 (13.4%) | 12030 (12.0%) | 1951 (19.0%) | 4939 (8.8%) | 3739 (8.8%) |
| 07/2022–10/2022 | 1515 (16.6%) | 125 (21.2%) | 543 (14.3%) | 448 (13.4%) | 9866 (9.9%) | 1453 (14.1%) | 6166 (11.0%) | 4002 (9.4%) |
| Obesity | ||||||||
| 0 | 6055 (66.2%) | 422 (71.5%) | 2230 (58.9%) | 1926 (57.6%) | 62750 (62.8%) | 6141 (59.8%) | 21525 (38.3%) | 21711 (51.1%) |
| 1 | 3085 (33.8%) | 168 (28.5%) | 1556 (41.1%) | 1420 (42.4%) | 37132 (37.2%) | 4135 (40.2%) | 34701 (61.7%) | 20766 (48.9%) |
| PMCA | ||||||||
| 0 | 4333 (47.4%) | 311 (52.7%) | 1938 (51.2%) | 1552 (46.4%) | 67424 (67.5%) | 7594 (73.9%) | 41294 (73.4%) | 27868 (65.6%) |
| 1 | 1435 (15.7%) | 79 (13.4%) | 534 (14.1%) | 524 (15.7%) | 18614 (18.6%) | 1564 (15.2%) | 8820 (15.7%) | 8692 (20.5%) |
| 2 | 3372 (36.9%) | 200 (33.9%) | 1314 (34.7%) | 1270 (38.0%) | 13844 (13.9%) | 1118 (10.9%) | 6112 (10.9%) | 5917 (13.9%) |
| Negative tests prior entry | ||||||||
| 0 | 6038 (66.1%) | 407 (69.0%) | 2671 (70.5%) | 2301 (68.8%) | 73195 (73.3%) | 7908 (77.0%) | 45852 (81.5%) | 32592 (76.7%) |
| 1 | 1445 (15.8%) | 97 (16.4%) | 521 (13.8%) | 497 (14.9%) | 15999 (16.0%) | 1440 (14.0%) | 6650 (11.8%) | 6233 (14.7%) |
| 2 | 641 (7.0%) | 32 (5.4%) | 225 (5.9%) | 238 (7.1%) | 5875 (5.9%) | 519 (5.1%) | 2169 (3.9%) | 2146 (5.1%) |
| >=3 | 1016 (11.1%) | 54 (9.2%) | 369 (9.7%) | 310 (9.3%) | 4813 (4.8%) | 409 (4.0%) | 1555 (2.8%) | 1506 (3.5%) |
| Vaccine dosage | ||||||||
| 0 | 7860 (86.0%) | 469 (79.5%) | 3347 (88.4%) | 3015 (90.1%) | 82136 (82.2%) | 7256 (70.6%) | 46760 (83.2%) | 37252 (87.7%) |
| 1 | 240 (2.6%) | 22 (3.7%) | 80 (2.1%) | 71 (2.1%) | 2878 (2.9%) | 474 (4.6%) | 1667 (3.0%) | 1159 (2.7%) |
| >=2 | 1040 (11.4%) | 99 (16.8%) | 359 (9.5%) | 260 (7.8%) | 14868 (14.9%) | 2546 (24.8%) | 7799 (13.9%) | 4066 (9.6%) |